Last reviewed · How we verify
MK0826, /Duration of Treatment : 8 Weeks
MK0826, /Duration of Treatment : 8 Weeks is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development.
MK0826 is a selective inhibitor of a specific molecular target being evaluated in phase 3 clinical trials.
At a glance
| Generic name | MK0826, /Duration of Treatment : 8 Weeks |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Without publicly disclosed mechanism details for MK0826, the exact molecular target and pharmacological action cannot be reliably specified. The drug is in phase 3 development by Merck Sharp & Dohme LLC with an 8-week treatment duration in the trial design.
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Effectiveness of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-abdominal Infections in Adults (0826-802) (PHASE3)
- Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK0826, /Duration of Treatment : 8 Weeks CI brief — competitive landscape report
- MK0826, /Duration of Treatment : 8 Weeks updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI